A modern approach to the treatment of hepatitis C patients using erbisol ultrapharm

Hepatitis C virus is the cause of acute and chronic hepatitis, leading to the development of liver cirrhosis and hepatocellular carcinoma. The result of antiviral therapy of chronic liver diseases is determined by a number of so-called "host factors". Among which, liver steatosis, iron overload, excess body weight of the patient, immunosuppression, alcohol abuse, degree of liver fibrosis, drug addiction, low initial activity of AlAT (less than 2 norms) have a negative value. In chronic viral hepatitis C and B, Erbisol ULTRApharm is injected in / in a jet of 2 ml in the morning and 2 ml (diluted to 20 ml of 0.9% sodium chloride solution) in the evening daily or in / m 2 ml 2 times a day in the morning and evening for 20 days against the background of basic detoxification therapy, and then for 60 days - intravenous 2 ml in the evening every 72 hours or intravenous 2 ml in the evening every 48 hours. A total of 40-70 ampoules of 2 ml per course. After a 10-14-day break, repeated courses of treatment should be carried out, the number of which is determined by the severity of the pathological process. The minimum duration of treatment is 6 months (2 courses), however, with positive dynamics of treatment, the first course can be extended to 6 months and the drug can be administered in / m 2 ml in the evening every 48 hours for 160 days.